ArticleAntimicrobial agents and chemotherapy2011
In vitro susceptibility of Madurella mycetomatis to posaconazole and terbinafine.
Article in Antimicrobial agents and chemotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Eumycetoma causative agents: A systematic review to inform the World Health Organization priority list of fungal pathogens.Medical mycology · 2024Pooled it
- The combination of amoxicillin-clavulanic acid and ketoconazole in the treatment of Madurella mycetomatis eumycetoma and Staphylococcus aureus co-infection.PLoS neglected tropical diseases · 2014Trial
- A conserved grain-associated immunosuppressive niche in Sudanese patients with mycetoma.PLoS neglected tropical diseases · 2026Observational
- Eumycetoma: pathogenesis, current treatments, and the search for new drugs.Applied microbiology and biotechnology · 2025Review
- An updated list of eumycetoma causative agents and their differences in grain formation and treatment response.Clinical microbiology reviews · 2024Review
- An update on the development of novel antifungal agents for eumycetoma.Frontiers in pharmacology · 2023Review
- Madurella mycetomatis grains within a eumycetoma lesion are clonal.Medical mycology · 2022Article
- In vitro susceptibility testing for black grain eumycetoma causative agents.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2021Article
- Development and Validation of anAntimicrobial agents and chemotherapy · 2021Article
- Diagnostic implications of mycetoma derived from Madurella pseudomycetomatis isolates from Mexico.Journal of the European Academy of Dermatology and Venereology : JEADV · 2020Article
- Madurella mycetomatis causing eumycetoma medical treatment: The challenges and prospects.PLoS neglected tropical diseases · 2020Review
- Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim.The Journal of antimicrobial chemotherapy · 2020Article
- Pyomelanin Secretion in Madurella mycetomatis Interferes with Spectrophotometric Endpoint Reading Using the Sensititre YeastOne alamarBlue Assay but Not with Visual Endpoint Reading.Antimicrobial agents and chemotherapy · 2019Article
- Addressing the most neglected diseases through an open research model: The discovery of fenarimols as novel drug candidates for eumycetoma.PLoS neglected tropical diseases · 2018Article
- Review of 21 cases of mycetoma from 1991 to 2014 in Rio de Janeiro, Brazil.PLoS neglected tropical diseases · 2017Article
- The in vitro antifungal activity of sudanese medicinal plants against Madurella mycetomatis, the eumycetoma major causative agent.PLoS neglected tropical diseases · 2015Article
- In vitro interaction of currently used azoles with terbinafine against Madurella mycetomatis.Antimicrobial agents and chemotherapy · 2015Article
- Last generation triazoles for imported eumycetoma in eleven consecutive adults.PLoS neglected tropical diseases · 2014Article
- Mycetoma medical therapy.PLoS neglected tropical diseases · 2014Review
- Madurella mycetomatis is highly susceptible to ravuconazole.PLoS neglected tropical diseases · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Presently, therapy of eumycetoma in Sudan is still based on surgery combined with prolonged ketoconazole therapy. This usually results in a poor clinical outcome. To determine if posaconazole and terbinafine could offer better therapeutic alternatives, the in vitro susceptibilities of 34 Madurella mycetomatis strains were determined. It appeared that posaconazole was highly active against M. mycetomatis but terbinafine was only moderately active. Since posaconazole has an excellent safety profile, it might provide an important alternative in mycetoma therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.